Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping

Candida auris is an emerging worldwide fungal pathogen. Over the past 20 years, 61 patient isolates of C. auris (4 blood and 57 ear) have been obtained from 13 hospitals in Korea. ABSTRACT Candida auris is an emerging worldwide fungal pathogen. Over the past 20 years, 61 patient isolates of C. auris (4 blood and 57 ear) have been obtained from 13 hospitals in Korea. Here, we reanalyzed those molecularly identified isolates using two matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) systems, including Biotyper and Vitek MS, followed by antifungal susceptibility testing, sequencing of the ERG11 gene, and genotyping. With a research-use-only (RUO) library, 83.6% and 93.4% of the isolates were correctly identified by Biotyper and Vitek MS, respectively. Using an in vitro diagnostic (IVD) library of Vitek MS, 96.7% of the isolates were correctly identified. Fluconazole-resistant isolates made up 62.3% of the isolates, while echinocandin- or multidrug-resistant isolates were not found. Excellent essential (within two dilutions, 96.7%) and categorical agreements (93.4%) between the Clinical and Laboratory Standards Institute (CLSI) and Vitek 2 (AST-YS07 card) methods were observed for fluconazole. Sequencing ERG11 for all 61 isolates revealed that only 3 fluconazole-resistant isolates showed the Erg11p amino acid substitution K143R. All 61 isolates showed identical multilocus sequence typing (MLST). Pulsed-field gel electrophoresis (PFGE) analyses revealed that both blood and ear isolates had the same or similar patterns. These results show that MALDI-TOF MS and Vitek 2 antifungal susceptibility systems can be reliable diagnostic tools for testing C. auris isolates from Korean hospitals. The Erg11p mutation was seldom found among Korean isolates of C. auris, and multidrug resistance was not found. Both MLST and PFGE analyses suggest that these isolates are genetically similar.

[1]  H. Badali,et al.  Candida auris otomycosis in Iran and review of recent literature , 2019, Mycoses.

[2]  H. Badali,et al.  Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model , 2018, Mycoses.

[3]  A. Chowdhary,et al.  A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance , 2018, The Journal of antimicrobial chemotherapy.

[4]  R. Master,et al.  Rapid, Accurate Identification of Candida auris by Using a Novel Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS) Database (Library) , 2018, Journal of Clinical Microbiology.

[5]  H. Badali,et al.  In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris , 2017, Antimicrobial Agents and Chemotherapy.

[6]  M. Arendrup,et al.  Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment , 2017, The Journal of infectious diseases.

[7]  A. Chowdhary,et al.  Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally , 2017, PLoS pathogens.

[8]  S. Suh,et al.  Comparison of the Bruker Biotyper and VITEK MS Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Systems Using a Formic Acid Extraction Method to Identify Common and Uncommon Yeast Isolates , 2017, Annals of laboratory medicine.

[9]  J. Berman,et al.  Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel , 2017, Emerging infectious diseases.

[10]  Christina A. Cuomo,et al.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Parra-Giraldo,et al.  Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia , 2017, Emerging infectious diseases.

[12]  K. Carroll,et al.  Can Multidrug-Resistant Candidaauris Be Reliably Identified in Clinical Microbiology Laboratories? , 2016, Journal of Clinical Microbiology.

[13]  A. van Belkum,et al.  Identification and typing of the emerging pathogen Candida auris by matrix‐assisted laser desorption ionisation time of flight mass spectrometry , 2016, Mycoses.

[14]  P. Escribano,et al.  Risk factors for late recurrent candidaemia. A retrospective matched case-control study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  A. Chowdhary,et al.  Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  A. Chowdhary,et al.  Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method , 2015, Journal of Clinical Microbiology.

[17]  A. Chowdhary,et al.  Multidrug-resistant endemic clonal strain of Candida auris in India , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[18]  K. Agarwal,et al.  New Clonal Strain of Candida auris, Delhi, India , 2013, Emerging infectious diseases.

[19]  S. Suh,et al.  Accuracy of Species-Level Identification of Yeast Isolates from Blood Cultures from 10 University Hospitals in South Korea by Use of the Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry-Based Vitek MS System , 2013, Journal of Clinical Microbiology.

[20]  Jong-Hee Shin,et al.  First Three Reported Cases of Nosocomial Fungemia Caused by Candida auris , 2011, Journal of Clinical Microbiology.

[21]  S. Suh,et al.  Detection of Amphotericin B Resistance in Candida haemulonii and Closely Related Species by Use of the Etest, Vitek-2 Yeast Susceptibility System, and CLSI and EUCAST Broth Microdilution Methods , 2011, Journal of Clinical Microbiology.

[22]  S. Suh,et al.  Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. , 2011, Medical mycology.

[23]  S. Suh,et al.  Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  H. Yamaguchi,et al.  Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital , 2009, Microbiology and immunology.

[25]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[26]  S. Suh,et al.  Microevolution of Candida albicans Strains during Catheter-Related Candidemia , 2004, Journal of Clinical Microbiology.

[27]  M. Maiden,et al.  Optimization and Validation of Multilocus Sequence Typing for Candida albicans , 2003, Journal of Clinical Microbiology.